191 related articles for article (PubMed ID: 12905487)
1. Bisphosphonate resistance in Paget's disease of bone.
Joshua F; Epstein M; Major G
Arthritis Rheum; 2003 Aug; 48(8):2321-3. PubMed ID: 12905487
[TBL] [Abstract][Full Text] [Related]
2. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
3. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
Siris ES; Lyles KW; Singer FR; Meunier PJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
[TBL] [Abstract][Full Text] [Related]
4. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate space measurement and dosage requirement for intravenous clodronate treatment of Paget's disease.
Rutland M; Wattie D; Que L; Hassan IM; Cundy T
Calcif Tissue Int; 2002 Feb; 70(2):99-102. PubMed ID: 11870415
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Paget's disease of bone: a survey of clinical practice in Australia.
Walsh JP; Attewell R; Stuckey BG; Hooper MJ; Wark JD; Fletcher S; Ferrari V; Eisman JA
Bone; 2008 Jun; 42(6):1219-25. PubMed ID: 18353737
[TBL] [Abstract][Full Text] [Related]
8. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
[TBL] [Abstract][Full Text] [Related]
10. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
11. Paget's disease of bone: experience from a centre in southern India.
Anjali ; Thomas N; Rajaratnam S; Shanthly N; Oommen R; Seshadri MS
J Assoc Physicians India; 2006 Jul; 54():525-9. PubMed ID: 17089899
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
O'Doherty DP; Bickerstaff DR; McCloskey EV; Hamdy NA; Beneton MN; Harris S; Mian M; Kanis JA
J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
[TBL] [Abstract][Full Text] [Related]
13. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another.
Gutteridge DH; Ward LC; Stewart GO; Retallack RW; Will RK; Prince RL; Criddle A; Bhagat CI; Stuckey BG; Price RI; Kent GN; Faulkner DL; Geelhoed E; Gan SK; Vasikaran S
J Bone Miner Res; 1999 Oct; 14 Suppl 2():79-84. PubMed ID: 10510219
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of resistant Paget's disease of bone with pamidronate.
Mallette LE
Arch Intern Med; 1989 Dec; 149(12):2765-7. PubMed ID: 2596945
[TBL] [Abstract][Full Text] [Related]
15. The effects of intravenous alendronate in Paget's disease of bone.
O'Doherty DP; McCloskey EV; Vasikaran S; Khan S; Kanis JA
J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285
[TBL] [Abstract][Full Text] [Related]
16. [Factors that determine intensity of response to treatment with tiludronate in Paget's disease].
Morales Piga A; Abraira Santos V; Rey Rey JS; de Abajo Iglesias F
Med Clin (Barc); 1998 Feb; 110(7):254-8. PubMed ID: 9562949
[TBL] [Abstract][Full Text] [Related]
17. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
18. Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
Gray RE; Yates AJ; Preston CJ; Smith R; Russell RG; Kanis JA
Q J Med; 1987 Sep; 64(245):755-67. PubMed ID: 2966965
[TBL] [Abstract][Full Text] [Related]
19. Pamidronate infusions for the treatment of Paget's disease of bone.
Mazieres B; Ahmed I; Moulinier L; Bon E; Cantagrel A; Laroche M
Rev Rhum Engl Ed; 1996 Jan; 63(1):36-43. PubMed ID: 9064108
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
Adami S; Salvagno G; Guarrera G; Montesanti F; Garavelli S; Rosini S; Lo Cascio V
Calcif Tissue Int; 1986 Oct; 39(4):226-9. PubMed ID: 2947663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
